Enantis’ FGF2-STAB® licensed by Defined Bioscience for use in stem cell media

Enantis recently concluded a licensing agreement with US-based company Defined Bioscience for global use of our patented FGF2-STAB® technology, for use alone and in stem cell media formulations.

“Defined Bioscience is excited to offer FGF2-STAB® to its customers,” said Dr. Steven Rees, CEO of Defined Bioscience. “Thermostable, high-functioning growth factors are critical to the stem cell culture industry, and innovations like this will pave the way for cost-effective, next-generation technologies in the space.”

FGF2-STAB®, originally coined FGF2-G3, was developed by Enantis and Masaryk University, using computational methods to improve thermostability of the wild-type sequence of fibroblast growth factor 2 (FGF2-WT or bFGF). While FGF2-WT quickly destabilizes in standard stem cell culture conditions, FGF2-STAB® retains full biological activity even after five days at 37°C, allowing for a more homogenous, undifferentiated stem cell culture, less frequent medium changes, and weekend-free cell culture scheduling.

“With Defined Bioscience, we share the vision of enabling weekend-free cultivations to scientists all over the world. Therefore, we are happy that our key product will be part of the innovative stem cell culture media being developed at Defined Bioscience” says Roman Badik, CEO of Enantis. “The license agreement we just concluded will be beneficial for both our growing businesses”.

Enantis and Qkine sign a licensing deal to bring hyperstable FGF2-STAB® to the global stem cell community

Enantis, a biotechnology spin-off company from Masaryk University, and Qkine, Cambridge University spin-out, have concluded a licensing deal for Qkine to use Enantis’s patented FGF2-STAB® technology globally and develop new product-lines based on the unique biochemical properties of the protein.

FGF2-STAB® is a hyperstable form of FGF-2 (bFGF), a core reagent for stem cell culture. This optimised form of the protein does not degrade in culture media leading to a range of applications in enhanced weekend-free stem cell culture media and advanced chemically defined systems, such as those needed in the cultured meat industry.

“With the licensing of FGF2-STAB®, Qkine is continuing to build its portfolio of the most innovative and highest quality growth factors for stem cell biology” says Dr Catherine Elton, Qkine CEO. “We are delighted to work with the team at Enantis, who share our ambition to drive innovation and provide opportunities for the stem cell sector and emerging fields including cellular agriculture and 3D cell culture.”

FGF2-STAB®, originally published in the scientific literature as FGF2-G3, was developed by Enantis and Masaryk University. The proprietary computational platform was used to explore the structure of the protein and selectively exchange amino-acids in the proteins to enhance thermostability without compromising biological function. The same approach was used successfully by Enantis for other members of this family of proteins that have therapeutic and cosmetic applications.

“To meet the growing demand for our key product, we have decided to partner with Qkine, specialists within their field with a great distribution network at their disposal” says Roman Badik, CEO of Enantis. “This licensing deal will be beneficial for both our dynamic small biotechnology companies and provide future opportunities we will grow together”, he added.

About Enantis

Enantis is a private biotechnology company founded as a spin-off from Masaryk University, Czech Republic. Enantis’ expertise is based on vast experience in protein engineering and state-of-the-art software tools. Our key product, FGF2-STAB®, is a patented thermostable form of basic fibroblast growth factor that can revolutionize stem cell culturing. This protein is 50-times more stable than its native counterpart and has a fully retained biological activity. We have other thermostable growth factors in our pipeline. 

About Qkine

Qkine is a Cambridge, UK-based manufacturer of high purity, animal-free growth factors, cytokines and other complex proteins. Qkine combines proprietary production processes with protein engineering technology to tackle fundamental biological and scale-up challenges for the fast-growing stem cell, organoid, regenerative medicine and cultured meat sectors. Visit qkine.com.

Enantis is searching for a Laboratory Technician!

Enantis hledá odborného laboratorního technika/techničku!

We would like to attract a responsible and friendly person with the right lab skills to complement our team. The person we seek will be responsible for development and recombinant production of our cosmetic and therapeutic proteins.

Would you like to work in a modern environment of an innovative spin-off biotech company? Are you keen to learn new skills and speak English? Do not hesitate to apply, the call is open till the end of the week.

More info in the job advert HERE (only in Czech)

#biotech #hiring #team #research #researchjobs #brnoregion #job #innovation #careers #recruitment

We would like to welcome another member into our patent family!

Singaporean patent has been granted to Enantis and Masaryk University for the use of our thermostable FGF (FGF2-STAB®).

We are eagerly awaiting patents being granted in other territories.

#patents #intellectualproperty #biotechnologies #brnoregion #ip

Enantis is searching for a Chief Technology/Scientific Officer. 

Get in touch if you’re interested!

See the full advert HERE

Enantis will present at this year’s edition of Nordic Life Science Days Digital that take place on 20-23 April 2021. We have prepared a pitch deck to promote our products and services and would like to initiate new partnerships during this event. Tune in for our pre-recorded presentation any time during the conference.

https://www.nlsdays.com/

Would you like to meet us at this conference? Do not hesitate to get in touch and we can arrange an online meeting.

Looking forward to online-meet you there!

#lifescience #conference #biotechnology #event

Bára Cihlová is a young Czech scientist who has been admitted to Oxford University to study viral enzymes. Unfortunately, the studies in Oxford are not just extremely difficult but also financially demanding, especially after Brexit when the fees for EU-based students quadrupled. Thus, Bára decided to raise money for her studies by an unconvential but efficient way – crowdfunding https://www.donio.cz/baracihlova.

Enantis decided to support her campaign financially and would like to highlight this case to other individuals and companies who might be able to help this bright student. Who knows, maybe Bára will make a breakthrough in her science career and help us all in return!

After the European patent, Enantis and Masaryk University would like to announce that an Australian patent has been granted. This patent covers the the use of our thermostable FGF (FGF2-STAB®).

We are eagerly awaiting patents being granted in other territories.

#patents #intellectualproperty #biotechnologies #brnoregion